Navigation Links
Amgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting
Date:12/5/2012

diagnosed in children.7 ITP affects about twice as many adult women as men.8

About Nplate® (romiplostim)
Nplate® (romiplostim) is the first FDA-approved treatment specifically for adult chronic ITP. It is also being investigated for potential use in children ages 12 months to 18 years old with persistent severe thrombocytopenia.

In the U.S., Nplate is indicated for the treatment of thrombocytopenia in patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than chronic ITP.  Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. Nplate should not be used in an attempt to normalize platelet counts.

For more information about Nplate, please visit www.Nplate.com.

Important Safety Information
The risks associated with Nplate include progression of MDS to acute myelogenous leukemia (AML) in patients with MDS, thrombotic/thromboembolic complications, bone marrow reticulin formation and risk for bone marrow fibrosis, worsened thrombocytopenia after cessation of Nplate, and lack or loss of response to Nplate. Medication errors including overdose and underdose have been reported in patients receiving Nplate. In the placebo-controlled studies, headache was the most commonly reported adverse drug reaction.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medici
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
3. Amgen Announces 2012 Third Quarter Dividend
4. Amgen to Present at the Leerink Swann Global Healthcare Conference
5. Amgen to Acquire Micromet
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
8. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
9. Amgen Announces 2012 First Quarter Dividend
10. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
11. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... OTTAWA, Ontario , Jan. 14, 2014   Kinaxis ®, ... ( SCM ) and sales and operations planning ( S&OP ... the Biomanufacturing Summit , which will be held at ...  At the conference, join Kinaxis customer Elisabeth Kaszas , ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental ... about dual arch impressions on its dental blog. ... blog entry serves up a list of tips to help ... by Dr. David Little as he crafts a porcelain crown ...
(Date:1/14/2014)... 2014 Independent publisher Bitingduck Press, with ... Canada, has big ideas for 2014 in production and ... are to produce high-quality, low-cost, DRM-free ebooks and to ... , The first major development will be bookstore ...
Breaking Biology Technology:RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... the Netherlands, February 24 ,Amsterdam Molecular Therapeutics (Euronext: AMT), a leader ... the year of 2008. , Highlights, ... delay of the announced, filing date ... - Positive clinical data on GlyberaTM, ...
... SPRINGS, Colo., Feb. 23 The National Academy of ... 2009 finds deficiencies in the nation,s forensic science system ... The report also calls for the development of accreditation ... a code of ethics for experts in all aspects ...
... 23 Texcel Medical, LLC, a full service ... company, has announced the appointment of Barry ... functions at Texcel Medical , which helps ... infrastructure and expertise they need to accelerate the ...
Cached Biology Technology:Amsterdam Molecular Therapeutics Reports Full Year Results 2008 2Amsterdam Molecular Therapeutics Reports Full Year Results 2008 3Strengthening Forensic Toxicology in the United States: The American Board of Forensic Toxicology Response to the National Academy of Sciences Recommendations 2Texcel Medical Appoints Barry Smith as President, CEO 2
(Date:7/9/2014)... that can attack soybean crops, why would charcoal rot ... University of Illinois scientists cite the earth,s changing climate ... the fungus that causes charcoal rot. , Fungi may ... Macrophomina phaseolina , the fungus that causes charcoal ... the climate continues to change and we see more ...
(Date:7/9/2014)... shows that the population is 3.79 million breeding ... Adlie penguins have long been considered a key ... of climate change and fishing in the Southern ... from Stony Brook University and University of Minnesota ... monitoring of Adlie penguins across their entire breeding ...
(Date:7/9/2014)... candidate developed by researchers at the NIH,s ... and its collaborators to treat sickle cell ... BioScience business. The drug candidate, Aes-103, is ... underlying molecular mechanism of sickle cell disease. ... activities required for regulatory approval and commercialization. ...
Breaking Biology News(10 mins):Climate change provides good growing conditions for charcoal rot in soybeans 2Climate change provides good growing conditions for charcoal rot in soybeans 3New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4
... with intellectual and developmental disabilities living in family ... routine dental care than those living in institutions, ... associate professor Catherine Binkley, D.D.S., Ph.D. These individuals ... to have poor oral hygiene, increased decay and ...
... shows that following a vegetarian diet and exercising at least ... in African Americans, who are twice as likely to be ... "These findings are encouraging for preventing type 2 diabetes ... disease than other populations," said Serena Tonstad, MD, a professor ...
... called "the trots," "Montezuma,s Revenge," "the runs" and worse. But ... a medicine that could go straight to the offending bacteria ... come true if work by Texas A&M University scientists stays ... Station. A "medicine that grows" is how the phage ...
Cached Biology News:UofL researcher to develop oral health plan for those with IDD 2Vegetarian diet, physical activity protect against diabetes in black population, study shows 2Texas A&M center confronts antibiotic crisis with potential new bacterial treatment 2Texas A&M center confronts antibiotic crisis with potential new bacterial treatment 3Texas A&M center confronts antibiotic crisis with potential new bacterial treatment 4
...
These 22x40mm rectangular No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick. • Approx. Pcs Oz : 73...
... Experion software, PC, is used to ... data obtained from the Experion automated ... in electropherogram and simulated gel views ... calculations in a Results table. This ...
...
Biology Products: